

KERYX BIOPHARMACEUTICALS INC

Form 4

July 19, 2006

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
WEISS MICHAEL S

(Last) (First) (Middle)

C/O KERYX  
BIOPHARMACEUTICALS,  
INC., 750 LEXINGTON AVE

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading  
Symbol  
KERYX  
BIOPHARMACEUTICALS INC  
[KERX]

3. Date of Earliest Transaction  
(Month/Day/Year)  
07/18/2006

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☐ 10% Owner  
☒ Officer (give title below) ☐ Other (specify below)  
Chairman and CEO

6. Individual or Joint/Group Filing(Check  
Applicable Line)

☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
Common Stock	07/18/2006		M		10,000	A	\$ 1.3	25,000	D
Common Stock	07/18/2006		S <sup>(1)</sup>		1,000	D	\$ 11.82	24,000	D
Common Stock	07/18/2006		S <sup>(1)</sup>		1,500	D	\$ 11.76	22,500	D
Common Stock	07/18/2006		S <sup>(1)</sup>		1,000	D	\$ 11.6	21,500	D

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 4

Common Stock	07/18/2006	S <sup>(1)</sup>	1,500	D	\$ 11.58	20,000	D
Common Stock	07/18/2006	S <sup>(1)</sup>	1,400	D	\$ 11.7	18,600	D
Common Stock	07/18/2006	S <sup>(1)</sup>	1,000	D	\$ 11.512	17,600	D
Common Stock	07/18/2006	S <sup>(1)</sup>	1,000	D	\$ 11.5	16,600	D
Common Stock	07/18/2006	S <sup>(1)</sup>	1,000	D	\$ 11.414	15,600	D
Common Stock	07/18/2006	S <sup>(1)</sup>	600	D	\$ 11.437	15,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	\$ 1.3	07/18/2006		M		10,000	<u>(2)</u>	12/23/2003 <sup>(3)</sup>	12/24/2012	Common Stock	10,000

## Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
WEISS MICHAEL S C/O KERYX BIOPHARMACEUTICALS, INC. 750 LEXINGTON AVE NEW YORK, NY 10022	X Chairman and CEO

## Signatures

/s/ Michael S.  
Weiss

07/19/2006

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The shares of common stock were sold pursuant to Mr. Weiss' Rule 10b5-1 trading plan with a brokerage firm dated December 30, 2005.
- (2) The options were exercised pursuant to Mr. Weiss' Rule 10b5-1 trading plan with a brokerage firm dated December 30, 2005.
- (3) All options have vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.